The authors have designated this AOP as all rights reserved. Re-use in any form requires advanced permission from the authors.

AOP: 660

Title

A descriptive phrase which references both the Molecular Initiating Event and Adverse Outcome.It should take the form “MIE leading to AO”. For example, “Aromatase inhibition leading to reproductive dysfunction” where Aromatase inhibition is the MIE and reproductive dysfunction the AO. In cases where the MIE is unknown or undefined, the earliest known KE in the chain (i.e., furthest upstream) should be used in lieu of the MIE and it should be made clear that the stated event is a KE and not the MIE.  More help

Activation of aryl hydrocarbon receptor (AhR) leading to preeclampsia via COX-2/PPAR-gamma-mediated trophoblast dysfunction

Short name
A name that succinctly summarises the information from the title. This name should not exceed 90 characters. More help
AhR activation leading to preeclampsia via COX-2/PPAR-gamma-mediated dysfunction
The current version of the Developer's Handbook will be automatically populated into the Handbook Version field when a new AOP page is created.Authors have the option to switch to a newer (but not older) Handbook version any time thereafter. More help
Handbook Version v2.8

Graphical Representation

A graphical representation of the AOP.This graphic should list all KEs in sequence, including the MIE (if known) and AO, and the pair-wise relationships (links or KERs) between those KEs. More help
Click to download graphical representation template Explore AOP in a Third Party Tool

Authors

The names and affiliations of the individual(s)/organisation(s) that created/developed the AOP. More help

YuCheng Nien. Department of Obstetrics, Gynecology & Women's Health, Taichung Veterans General Hospital, Taichung, Taiwan.

Point of Contact

The user responsible for managing the AOP entry in the AOP-KB and controlling write access to the page by defining the contributors as described in the next section.   More help
YuCheng Nien   (email point of contact)

Contributors

Users with write access to the AOP page.  Entries in this field are controlled by the Point of Contact. More help
  • YuCheng Nien

Coaches

This field is used to identify coaches who supported the development of the AOP.Each coach selected must be a registered author. More help

OECD Information Table

Provides users with information concerning how actively the AOP page is being developed and whether it is part of the OECD Workplan and has been reviewed and/or endorsed. OECD Project: Assigned upon acceptance onto OECD workplan. This project ID is managed and updated (if needed) by the OECD. OECD Status: For AOPs included on the OECD workplan, ‘OECD status’ tracks the level of review/endorsement of the AOP . This designation is managed and updated by the OECD. Journal-format Article: The OECD is developing co-operation with Scientific Journals for the review and publication of AOPs, via the signature of a Memorandum of Understanding. When the scientific review of an AOP is conducted by these Journals, the journal review panel will review the content of the Wiki. In addition, the Journal may ask the AOP authors to develop a separate manuscript (i.e. Journal Format Article) using a format determined by the Journal for Journal publication. In that case, the journal review panel will be required to review both the Wiki content and the Journal Format Article. The Journal will publish the AOP reviewed through the Journal Format Article. OECD iLibrary published version: OECD iLibrary is the online library of the OECD. The version of the AOP that is published there has been endorsed by the OECD. The purpose of publication on iLibrary is to provide a stable version over time, i.e. the version which has been reviewed and revised based on the outcome of the review. AOPs are viewed as living documents and may continue to evolve on the AOP-Wiki after their OECD endorsement and publication.   More help
OECD Project # OECD Status Reviewer's Reports Journal-format Article OECD iLibrary Published Version
This AOP was last modified on November 17, 2026 19:51

Revision dates for related pages

Page Revision Date/Time
Activation, AhR May 31, 2025 07:56
increase, Preeclampsia May 31, 2021 10:58
Increase, COX-2 expression March 20, 2018 16:33
reduced production, VEGF March 28, 2018 11:48
Altered, Cardiovascular development/function September 16, 2017 10:14
Decreased trophoblast invasion/migration November 17, 2026 01:45
Increase, Prostaglandin E2 concentration November 17, 2026 01:44
Decreased, PPAR-gamma activation October 30, 2023 09:07
Increase, Extracellular matrix deposition February 10, 2026 04:44
Decreased, MMP November 17, 2026 01:23
increase, placental insufficiency May 31, 2021 10:54
Activation, AhR leads to Increase, COX-2 expression November 17, 2026 01:34
Increase, COX-2 expression leads to Increase, Prostaglandin E2 concentration November 17, 2026 01:26
Increase, COX-2 expression leads to Altered, Cardiovascular development/function March 28, 2018 13:24
Increase, Prostaglandin E2 concentration leads to Decreased, PPAR-gamma activation November 17, 2026 02:03
Decreased, PPAR-gamma activation leads to Decreased, MMP November 17, 2026 01:31
Decreased, MMP leads to Increase, ECM deposition November 17, 2026 01:32
Increase, ECM deposition leads to Cellular dysfunction (human placenta trophoblast cells) November 17, 2026 01:32
Cellular dysfunction (human placenta trophoblast cells) leads to increase, placental insufficiency November 17, 2026 01:57
increase, placental insufficiency leads to reduced production, VEGF November 17, 2026 02:00
reduced production, VEGF leads to Altered, Cardiovascular development/function November 17, 2026 02:04
reduced production, VEGF leads to increase, Preeclampsia November 17, 2026 01:37
Altered, Cardiovascular development/function leads to increase, Preeclampsia November 17, 2026 01:33
N(6)-Carboxymethyllysine November 16, 2026 21:51
Selected AHR Ligands November 29, 2016 21:20

Abstract

A concise and informative summation of the AOP under development that can stand-alone from the AOP page. The aim is to capture the highlights of the AOP and its potential scientific and regulatory relevance. More help

Preeclampsia (PE) is a severe pregnancy-specific hypertensive disorder affecting 3-5% of pregnancies globally and is a leading cause of maternal and perinatal morbidity and mortality, with significantly elevated risk and clinical severity among women with diabetes. This Adverse Outcome Pathway (AOP) was initiated to elucidate the mechanistic linkage between diabetic hyperglycemia and exacerbated PE pathology via the aryl hydrocarbon receptor (AhR) signaling axis. Under hyperglycemic conditions, non-enzymatic glycoxidation and lipid peroxidation promote the accumulation of N-ε-carboxymethyllysine (CML), which acts as a stressor to trigger the Molecular Initiating Event (MIE): Activation, AhR (Event 18) in placental trophoblasts and endothelial cells. Aberrant AhR activation subsequently induces Increase, COX-2 expression (Event 1269) and Increase, Prostaglandin E2 concentration (Event 2466). Excessive PGE2 signaling leads to Decreased, PPAR-gamma activation (Event 233), which in turn drives Decreased, MMP (Event 2467) activity and Increase, Extracellular matrix deposition (Event 1501) within the placental microenvironment. Together, matrix remodeling arrest and excessive ECM accumulation result in Decreased trophoblast invasion/migration (Event 2103), impairing uterine spiral artery remodeling and leading to placental insufficiency (Event 1892) and hypoxia. Placental ischemia subsequently triggers the release of anti-angiogenic factors, resulting in reduced production, VEGF (Event 948) and Altered, Cardiovascular development/function (Event 317)—manifesting as widespread maternal vascular endothelial dysfunction and vasoconstriction—which ultimately culminate in the Adverse Outcome (AO) of increase, Preeclampsia (Event 1893). Overall, the biological plausibility of this pathway is supported by moderate-to-strong empirical evidence from diabetic vascular/renal models demonstrating CML–AhR–COX-2/PGE2 signaling, alongside established roles of PPAR-γ, MMPs, and VEGF in placentation. However, major knowledge gaps remain regarding quantitative CML thresholds in early human gestation and direct causal confirmation of the AhR–COX-2/PGE2–PPAR-γ cascade at the human maternal-fetal interface. Scientifically and regulatorily, this AOP provides an organizing framework for identifying early predictive biomarkers, evaluating developmental and reproductive toxicity (DART) of AhR ligands, and guiding targeted preventive interventions for high-risk diabetic pregnancies.

AOP Development Strategy

Context

Used to provide background information for AOP reviewers and users that is considered helpful in understanding the biology underlying the AOP and the motivation for its development.The background should NOT provide an overview of the AOP, its KEs or KERs, which are captured in more detail below. More help

Pregnant women with preexisting diabetes or gestational diabetes mellitus face a substantially elevated risk of developing severe PE and preterm birth. This Adverse Outcome Pathway (AOP) was developed to address a critical mechanistic question: How does a diabetic hyperglycemic microenvironment disrupt trophoblast invasion, angiogenic balance, and uterine spiral artery remodeling, thereby exacerbating the clinical severity of preeclampsia?

The primary objectives of developing this AOP are to 1. Document specialized placental and vascular biology: Synthesize cross-disciplinary evidence connecting diabetic nephropathic/vascular mechanisms (CML–AhR–COX-2/PGE2 signaling) with PPAR-γ downregulation, MMP suppression, extracellular matrix (ECM) remodeling, and placental angiogenesis (VEGF). 2. Establish the biological relevance of upstream molecular and cellular assays (e.g., serum CML-modified peptides, AhR activation, COX-2/PGE2 levels, PPAR-γ activity, MMP-2/MMP-9 expression, and VEGF production) alongside clinical angiogenic biomarkers (sFlt-1/PlGF ratio) to guide early risk stratification and targeted therapeutic interventions for high-risk diabetic pregnancies.

Strategy

Provides a description of the approaches to the identification, screening and quality assessment of the data relevant to identification of the key events and key event relationships included in the AOP or AOP network.This information is important as a basis to support the objective/envisaged application of the AOP by the regulatory community and to facilitate the reuse of its components.  Suggested content includes a rationale for and description of the scope and focus of the data search and identification strategy/ies including the nature of preliminary scoping and/or expert input, the overall literature screening strategy and more focused literature surveys to identify additional information (including e.g., key search terms, databases and time period searched, any tools used). More help

This Adverse Outcome Pathway (AOP) was developed using a cross-disease translational strategy, bridging well-characterized clinical pathology at the Adverse Outcome (AO) end with mechanistic molecular toxicology at the Molecular Initiating Event (MIE) end:

  1. Cross-Organ Mechanistic Extrapolation (Diabetic Nephropathy to Placenta): To explain the high clinical incidence and severity of PE in pregnancies complicated by diabetes mellitus or gestational diabetes mellitus (GDM), we extrapolated a validated diabetic vascular/renal mechanism (Lee et al., 2016), in which hyperglycemia-derived N-ε-carboxymethyllysine (CML) activates AhR (Event 18) to upregulate COX-2 (Event 1269) and PGE2 (Event 2466), driving extracellular matrix (ECM) deposition (Event 1501) and inflammatory cell infiltration.
  2. Placental Microenvironment Integration: We bridged the upstream inflammatory axis (Events 1269 and 2466) to downstream trophoblast and vascular dysfunction (Events 2103, 948, and 317) through PPAR-γ inactivation (Event 233) and MMP downregulation (Event 2467), integrating pregnancy-specific regulatory networks.

Summary of the AOP

This section is for information that describes the overall AOP.The information described in section 1 is entered on the upper portion of an AOP page within the AOP-Wiki. This is where some background information may be provided, the structure of the AOP is described, and the KEs and KERs are listed. More help

Events:

Molecular Initiating Events (MIE)
An MIE is a specialised KE that represents the beginning (point of interaction between a prototypical stressor and the biological system) of an AOP. More help
Key Events (KE)
A measurable event within a specific biological level of organisation. More help
Adverse Outcomes (AO)
An AO is a specialized KE that represents the end (an adverse outcome of regulatory significance) of an AOP. More help
Type Event ID Title Short name
MIE 18 Activation, AhR Activation, AhR
KE 1269 Increase, COX-2 expression Increase, COX-2 expression
KE 2466 Increase, Prostaglandin E2 concentration Increase, Prostaglandin E2 concentration
KE 233 Decreased, PPAR-gamma activation Decreased, PPAR-gamma activation
KE 2467 Decreased, MMP Decreased, MMP
KE 1501 Increase, Extracellular matrix deposition Increase, ECM deposition
KE 2103 Decreased trophoblast invasion/migration Cellular dysfunction (human placenta trophoblast cells)
KE 1892 increase, placental insufficiency increase, placental insufficiency
KE 948 reduced production, VEGF reduced production, VEGF
KE 317 Altered, Cardiovascular development/function Altered, Cardiovascular development/function
AO 1893 increase, Preeclampsia increase, Preeclampsia

Relationships Between Two Key Events (Including MIEs and AOs)

This table summarizes all of the KERs of the AOP and is populated in the AOP-Wiki as KERs are added to the AOP.Each table entry acts as a link to the individual KER description page. More help

Network View

This network graphic is automatically generated based on the information provided in the MIE(s), KEs, AO(s), KERs and Weight of Evidence (WoE) summary tables. The width of the edges representing the KERs is determined by its WoE confidence level, with thicker lines representing higher degrees of confidence. This network view also shows which KEs are shared with other AOPs. More help

Prototypical Stressors

A structured data field that can be used to identify one or more “prototypical” stressors that act through this AOP. Prototypical stressors are stressors for which responses at multiple key events have been well documented. More help

Life Stage Applicability

The life stage for which the AOP is known to be applicable. More help
Life stage Evidence
Pregnancy Moderate

Taxonomic Applicability

Latin or common names of a species or broader taxonomic grouping (e.g., class, order, family) can be selected.In many cases, individual species identified in these structured fields will be those for which the strongest evidence used in constructing the AOP was available. More help
Term Scientific Term Evidence Link
human Homo sapiens Moderate NCBI
mouse Mus musculus Moderate NCBI

Sex Applicability

The sex for which the AOP is known to be applicable. More help
Sex Evidence
Female Moderate

Overall Assessment of the AOP

Addressess the relevant biological domain of applicability (i.e., in terms of taxa, sex, life stage, etc.) and Weight of Evidence (WoE) for the overall AOP as a basis to consider appropriate regulatory application (e.g., priority setting, testing strategies or risk assessment). More help

 Support for Biological Plausibility of KERs

MIE => KE1: Activation, AhR leads to Increase, COX-2 expression

Biological Plausibility of the MIE => KE1 is high.

Rationale:  Ligand-bound aryl hydrocarbon receptor (AhR) undergoes conformational activation and translocates into the nucleus, where it heterodimerizes with the AhR nuclear translocator (ARNT). The resulting AhR/ARNT transcription factor complex specifically binds to xenobiotic response elements (XREs/DREs) located within the promoter region of the PTGS2 gene (encoding cyclooxygenase-2, COX-2). This genomic binding recruits transcriptional coactivators to directly drive COX-2 mRNA synthesis and protein expression. (Lee et al. (2016); Vogel et al. (2007))

KE1 => KE2: Increase, COX-2 expression leads to Increase, Prostaglandin E2 concentration

Biological Plausibility of the KE1 => KE2 is high.

Rationale:  Cyclooxygenase-2 (COX-2) functions as the rate-limiting enzyme converting membrane arachidonic acid into prostaglandin H2 (PGH2). PGH2 is subsequently isomerized to prostaglandin E2 (PGE2) via terminal microsomal prostaglandin E synthase-1 (mPGES-1). Elevated COX-2 protein level directly leads to a stoichiometric increase in PGE2 synthesis and extracellular secretion. (Lee et al. (2016); Li et al. (2015))

KE2 => KE3: Increase, Prostaglandin E2 concentration leads to Decreased, PPAR-gamma activation

Biological Plausibility of the KE2 => KE3 is high.

Rationale:  Extracellular PGE2 binds to G-protein coupled E-prostanoid receptors (EP2/EP4) on trophoblasts, activating intracellular cAMP/PKA and ERK1/2-MAPK kinase cascades. This signals inhibitory phosphorylation at serine residues within the N-terminal or ligand-binding domain of peroxisome proliferator-activated receptor gamma (PPAR-gamma), suppressing its nuclear translocation and DNA-binding activity. (Jia et al. (2022))

KE3 => KE4: Decreased, PPAR-gamma activation leads to Decreased, MMP

Biological Plausibility of the KE3 => KE4 is high.

Rationale:  Active PPAR-gamma functions as an essential positive transcriptional regulator of matrix metalloproteinases (MMP2 and MMP9) by binding to peroxisome proliferator response elements (PPREs) in their promoter regions. Suppression of PPAR-gamma activity abolishes this baseline transactivation and alters the MMP/TIMP stoichiometric balance, markedly reducing proMMP-2/9 expression and enzymatic cleavage. (Jia et al. (2022); Kobara et al. (2013))

KE4 => KE5: Decreased, MMP leads to Increase, ECM deposition

Biological Plausibility of the KE4 => KE5 is high.

Rationale:  MMP-2 and MMP-9 (type IV collagenases) are key endopeptidases responsible for degrading structural extracellular matrix (ECM) components, including Type IV collagen, fibronectin, and laminin. Suppression of MMP gelatinase activity arrests matrix degradation and turnover, leading to pericellular accumulation of structural matrix proteins and tissue fibrosis. (Lee et al. (2016); Bautista-Bautista et al. (2024))

KE5 => KE6: Increase, ECM deposition leads to Cellular dysfunction (human placenta trophoblast cells)

Biological Plausibility of the KE 5 => KE6 is high.

Rationale:  Excessive ECM deposition increases spatial biomechanical stiffness and creates dense physical barriers within the maternal decidua. Dense matrix physical constraints combined with altered integrin mechanotransduction physically restrict extravillous trophoblast (EVT) motility and invasion toward maternal spiral arteries. (Jiang et al. (2013); Tossetta et al. (2019))

KE6 => KE7: Cellular dysfunction (human placenta trophoblast cells) leads to increase, placental insufficiency

Biological Plausibility of the KE6 => KE7 is high.

Rationale:  Impaired EVT invasion prevents endovascular replacement of maternal subplacental uterine spiral artery endothelial and smooth muscle layers. Unremodeled spiral arteries remain high-resistance, low-flow vessels, causing chronic uteroplacental hypoperfusion, severe ischemia, and severe placental insufficiency. (Zhao et al. (2023/2025); Khankin et al. (2010))

KE7 => KE8: increase, placental insufficiency leads to reduced production, VEGF

Biological Plausibility of the KE7 => KE8 is high.

Rationale:  Ischemic and hypoxic syncytiotrophoblasts hypersecrete soluble fms-like tyrosine kinase-1 (sFlt-1). Secreted sFlt-1 functions as a high-affinity decoy receptor that binds and sequesters free vascular endothelial growth factor (VEGF) and placental growth factor (PlGF), dramatically reducing bioavailable circulating free VEGF levels. (Rana et al. (2019); AHA Organoid Model (2025))

KE8 => KE9: reduced production, VEGF leads to Altered, Cardiovascular development/function

Biological Plausibility of the KE8 => KE9 is high.

Rationale:  Free VEGF is mandatory for maintaining endothelial cell survival, fenestration integrity, and eNOS-mediated nitric oxide (NO) production. Depletion of free VEGF causes systemic endothelial injury, eNOS uncoupling, impaired vasorelaxation, and Endothelin-1 (ET-1) upregulation, triggering systemic arterial vasospasm. (Li et al. (2020); Zhou et al. (2019))

KE9 => AO: Altered, Cardiovascular development/function leads to increase, Preeclampsia

Biological Plausibility of the KE 9=> AO is high.

Rationale:  Systemic arterial vasospasm elevates total peripheral resistance, directly causing maternal gestational hypertension. Glomerular endotheliosis and podocyte injury disrupt the renal filtration barrier, causing proteinuria and fulfilling clinical criteria for Preeclampsia. (Roberts et al. (2021); Jiang et al. (2025))

 Support for essentiality of KEs

MIE: Activation, AhR

Essentiality of the MIE is high.

Rationale for Essentiality of the MIE in the AOP:  Genetic deletion of AhR (AhR -/-), siRNA-mediated AhR knockdown, or pharmacological inhibition using specific AhR antagonists (e.g., CH223191, biseugenol, or alpha-naphthoflavone) completely abolishes CML- or ligand-induced COX-2 upregulation. (Lee et al. (2016); Vogel et al. (2007))

KE1: Increase, COX-2 expression

Essentiality of the KE1 is high.

Rationale for Essentiality of the KE1 in the AOP:  Pharmacological inhibition of COX-2 using selective inhibitors (e.g., celecoxib, indomethacin, or low-dose aspirin) or COX-2 gene silencing directly blocks downstream PGE2 production and prevents its autocrine/paracrine accumulation. (Lee et al. (2016); Li et al. (2015))

KE2: Increase, Prostaglandin E2 concentration

Essentiality of the KE2 is high.

Rationale for Essentiality of the KE2 in the AOP:  Blocking upstream AhR/COX-2 signaling, neutralizing extracellular PGE2 with specific antibodies, or antagonizing EP2/EP4 receptors fully rescues PPAR-gamma nuclear localization and transcriptional transactivation. (Jia et al. (2022))

KE3: Decreased, PPAR-gamma activation

Essentiality of the KE3 is high.

Rationale for Essentiality of the KE3 in the AOP: Administration of synthetic PPAR-gamma agonists (e.g., rosiglitazone or pioglitazone) directly restores MMP-2 and MMP-9 expression and gelatinase activity, overcoming upstream PGE2-mediated suppression. (Jia et al. (2022); Kobara et al. (2013))

KE4: Decreased, MMP

Essentiality of the KE4 is high.

Rationale for Essentiality of the KE4 in the AOP: Restoring MMP activity via PPAR-gamma agonists or upstream AhR/COX-2 inhibition prevents excessive matrix deposition; conversely, broad-spectrum MMP inhibitors induce rapid, uncontrolled ECM accumulation. (Lee et al. (2016); Bautista-Bautista et al. (2024))

KE5: Increase, ECM deposition

Essentiality of the KE5 is high.

Rationale for Essentiality of the KE5 in the AOP: Enzymatic degradation of excess matrix components or preventing upstream AhR-driven ECM overproduction restores EVT invasion depth in Matrigel and Transwell invasion assays. (Jiang et al. (2013); Tossetta et al. (2019))

KE6: Cellular dysfunction (human placenta trophoblast cells)

Essentiality of the KE6 is high.

Rationale for Essentiality of the KE6 in the AOP: Reversing trophoblast invasion failure or blocking upstream AhR/COX-2 pathobiology restores endovascular spiral artery transformation and improves uteroplacental blood perfusion in animal models. (Zhao et al. (2023/2025); Khankin et al. (2010))

KE7: placental insufficiency

Essentiality of the KE7 is high.

Rationale for Essentiality of the KE7 in the AOP: Administration of sFlt-1 neutralizing antibodies, recombinant VEGF165, or relieving placental ischemia (via upstream pathway inhibition) directly restores bioavailable free VEGF concentrations. (Rana et al. (2019); AHA Organoid Model (2025))

KE8: reduced production, VEGF

Essentiality of the KE8 is high.

Rationale for Essentiality of the KE8 in the AOP: Exogenous VEGF supplementation or sFlt-1 antagonism restores endothelial eNOS activation and normalizes endothelium-dependent vasodilation in isolated maternal resistance arteries. (Li et al. (2020); Zhou et al. (2019))

KE9: Altered, Cardiovascular development/function

Essentiality of the KE9 is high.

Rationale for Essentiality of the KE9 in the AOP: Upstream blockade of the MIE (AhR antagonism) or early KEs (COX-2 inhibition via low-dose aspirin, PPAR-gamma activation, or sFlt-1 neutralization) prevents or significantly attenuates gestational hypertension and proteinuria. (Roberts et al. (2021); Jiang et al. (2025))

Domain of Applicability

Addressess the relevant biological domain(s) of applicability in terms of sex, life-stage, taxa, and other aspects of biological context. More help

The AOP660 applies to Homo sapiens (human), pregnancy, and female.

Essentiality of the Key Events

The essentiality of KEs can only be assessed relative to the impact of manipulation of a given KE (e.g., experimentally blocking or exacerbating the event) on the downstream sequence of KEs defined for the AOP. Consequently, evidence supporting essentiality is assembled on the AOP page, rather than on the independent KE pages that are meant to stand-alone as modular units without reference to other KEs in the sequence. The nature of experimental evidence that is relevant to assessing essentiality relates to the impact on downstream KEs and the AO if upstream KEs are prevented or modified. This includes: Direct evidence: directly measured experimental support that blocking or preventing a KE prevents or impacts downstream KEs in the pathway in the expected fashion. Indirect evidence: evidence that modulation or attenuation in the magnitude of impact on a specific KE (increased effect or decreased effect) is associated with corresponding changes (increases or decreases) in the magnitude or frequency of one or more downstream KEs. More help

Event

Direct Evidence

Indirect Evidence

MIE

***

***

KE1

***

***

KE2

**

***

KE3

***

***

KE4

***

**

KE5

**

***

KE6

***

***

KE7

***

***

KE8

***

***

KE9

***

***

Evidence Assessment

Addressess the biological plausibility, empirical support, and quantitative understanding from each KER in an AOP. More help

MIE => KE1 : Activation, AhR leads to Increase, COX-2 expression

Empirical Support of the MIE => KE1 is high.

Rationale: In diabetic mesangial cells and human placental/endothelial models, exposure to advanced glycation end-products (CML) or dioxin-like compounds triggers AhR nuclear translocation followed by a time- and concentration-dependent elevation of COX-2 expression. This response is completely absent in AhR-deficient models. (Lee et al. (2016); Vogel et al. (2007))

KE1 => KE2 : Increase, COX-2 expression leads to Increase, Prostaglandin E2 concentration

Empirical Support of the KE1 => KE2 is high.

Rationale: Quantitative assays in human trophoblasts, endothelial cells, and diabetic renal tissues demonstrate that COX-2 protein expression directly correlates with extracellular PGE2 concentrations in cell culture supernatants and tissue homgenates. (Lee et al. (2016); Li et al. (2015))

KE2 => KE3 : Increase, Prostaglandin E2 concentration leads to Decreased, PPAR-gamma activation

Empirical Support of the KE2 => KE3 is moderate.

Rationale: Treatment of human extravillous trophoblasts (EVTs) or vascular cells with exogenous PGE2 induces dose-dependent inhibition of PPAR-gamma reporter gene activity and reduces nuclear PPAR-gamma protein levels, mimicking pathology observed in preeclamptic placentas. (Jia et al. (2022))

KE3 => KE4 : Decreased, PPAR-gamma activation leads to Decreased, MMP

Empirical Support of the KE3 => KE4 is high.

Rationale: siRNA-mediated PPAR-gamma knockdown or pharmacological inhibition with GW9662 markedly reduces MMP-2/9 mRNA expression and gelatinase zymography activity in human HTR-8/SVneo trophoblast cells and extra-placental membranes. (Jia et al. (2022); Kobara et al. (2013))

KE4 => KE5 : Decreased, MMP leads to Increase, ECM deposition

Empirical Support of the KE4 => KE5 is high.

Rationale: In diabetic tissue models and human decidual cultures, reduced MMP-9 gelatinase activity quantitatively correlates with significant increases in Type IV collagen and Fibronectin deposition. (Lee et al. (2016); Bautista-Bautista et al. (2024))

KE5 => KE6 : Increase, ECM deposition leads to Cellular dysfunction (human placenta trophoblast cells)

Empirical Support of the KE5 => KE6 is moderate.

Rationale: Increased ECM substrate stiffness and dense Fibronectin/Collagen matrices significantly decrease HTR-8/SVneo migration speed and invasion capacity in vitro. (Jiang et al. (2013); Tossetta et al. (2019))

KE6 => KE7 : Cellular dysfunction (human placenta trophoblast cells) leads to increase, placental insufficiency

Empirical Support of the KE 6 => KE7 is high.

Rationale: Histopathological analysis of preeclamptic placentas consistently reveals shallow EVT invasion and unremodeled spiral arteries, directly correlating with reduced Doppler uteroplacental perfusion parameters. (Zhao et al. (2023/2025); Khankin et al. (2010))

KE7 => KE8 : increase, placental insufficiency leads to reduced production, VEGF

Empirical Support of the KE7 => KE8 is high. Rationale: In clinical preeclampsia cohorts and Reduced Uteroplacental Perfusion Pressure (RUPP) animal models, placental hypoxia directly drives a surge in serum sFlt-1 accompanied by a reciprocal collapse in bioavailable free VEGF. (Rana et al. (2019); AHA Organoid Model (2025))

KE8 => KE9 : reduced production, VEGF leads to Altered, Cardiovascular development/function

Empirical Support of the KE8 => KE9 is high.

Rationale: Exogenous sFlt-1 infusion in pregnant rodents induces systemic endothelial cell swelling, blunted vasodilation responses, and acute systemic vasoconstriction. (Li et al. (2020); Zhou et al. (2019))

KE9 => AO : Altered, Cardiovascular development/function leads to increase, Preeclampsia

Empirical Support of the KE9 => AO is high.

Rationale: Clinical trials and animal models demonstrate that reversing endothelial dysfunction directly alleviates hypertension and renal pathology, preventing progression to clinical Preeclampsia. (Roberts et al. (2021); Jiang et al. (2025))

Known Modulating Factors

Modulating factors (MFs) may alter the shape of the response-response function that describes the quantitative relationship between two KES, thus having an impact on the progression of the pathway or the severity of the AO.The evidence supporting the influence of various modulating factors is assembled within the individual KERs. More help

Modulating Factor (MF)

Influence or Outcome

KER(s) involved

Pre-existing Diabetes / GDM

Chronic hyperglycemia, advanced glycation end-product (N(6)-Carboxymethyllysine, CML) accumulation, significantly increases MIE activation sensitivity, accelerates the COX-2/PGE2 inflammatory cascade.

MIE/ KE1/ KE2

IDO1 Activity & Endogenous Ligands

Tryptophan metabolites (Kynurenine, ITE) maintains homeostatic maternal-fetal immune tolerance; exposure to xenobiotics suppresses IDO1, disrupting physiological AhR protective signaling.

MIE

Genetic Polymorphisms (AHR Variants)

AHR rs713150G minor allele variant drives differential placental AhR expression; clinically identified as a protective genetic factor against preeclampsia susceptibility.

MIE

Low-Dose Aspirin Prophylaxis

Cyclooxygenase (COX) inhibitor initiated prior to 16 weeks of gestation blunts downstream pro-inflammatory prostaglandin (PGE2) surges, effectively reducing preeclampsia incidence in high-risk pregnancies

KE1/ KE2

Exogenous AhR Modulators & Toxins

Dioxin-like compounds (TCDD) and Benzo[a]pyrene (B(a)P) exacerbate sFlt-1 hypersecretion and ECM accumulation.

MIE/ KE5/ KE8

Quantitative Understanding

Optional field to provide quantitative weight of evidence descriptors.  More help

The quantitative understanding of AOP 660 is currently categorized overall as Moderate, defined by a distinct temporal and scale-dependent hierarchy across biological levels of organization.

Upstream key events spanning the Molecular Initiating Event (MIE, AhR activation) to KE2 (PGE2 elevation) exhibit robust semi-quantitative dose- and time-response relationships in vitro within acute timeframes (hours to 48 h). In this early phase, chronic accumulation of N-ε-carboxymethyllysine (CML) under hyperglycemic stress eventually overcomes homeostatic negative feedback clearance driven by CYP1A1/CYP1A2 enzymes.

Midstream cell- and tissue-level events (KE3 to KE6: PGE2–PPAR-gamma repression, MMP-2/9 suppression, and ECM over-deposition) display moderate quantitative predictability; while specific PGE2 threshold concentrations and matrix stiffness values correlate directly with reduced extravillous trophoblast invasion in human explant models, quantitative inter-individual microenvironmental variations remain.

Conversely, downstream systemic events leading to the Adverse Outcome (KE7 to AO: placental insufficiency, sFlt-1/PlGF ratio surge, endothelial vasospasm, and preeclampsia) possess High quantitative predictive validity spanning weeks across gestation (weeks 12–20 to clinical presentation). Clinically validated biomarkers, particularly circulating sFlt-1/PlGF ratio thresholds (e.g., cutoffs of >38 or >85), reliably predict impending preeclampsia onset within 1 to 4 weeks.

Future incorporation of multi-scale toxicokinetic-toxicodynamic (TKTD) computational models will bridge early upstream CML-AhR threshold concentrations directly with downstream systemic vascular risks, advancing this framework into a fully quantitative risk-assessment tool for high-risk diabetic pregnancies.

Considerations for Potential Applications of the AOP (optional)

Addressess potential applications of an AOP to support regulatory decision-making.This may include, for example, possible utility for test guideline development or refinement, development of integrated testing and assessment approaches, development of (Q)SARs / or chemical profilers to facilitate the grouping of chemicals for subsequent read-across, screening level hazard assessments or even risk assessment. More help

Based on the weight-of-evidence (WoE) evaluation—supported by strong biological plausibility, moderate empirical evidence, and evolving quantitative predictability—this Adverse Outcome Pathway (AOP) serves as a robust mechanistic framework for hypothesis generation, early biomarker discovery, and screening-level hazard identification:

  1. Early Risk Stratification & Biomarker Discovery: By mechanistic bridging of diabetic hyperglycemia to placental vascular pathology, upstream and mid-stream Key Events—including maternal serum N-ε-carboxymethyllysine (CML), AhR activation (MIE, Event 18), COX-2/PGE2 elevation (Events 1269 & 2466), and MMP-2/9 suppression (Event 2467)—provide a panel of early-gestation mechanistic biomarkers. These complement established mid-to-late gestation angiogenic markers (such as the sFlt-1/PlGF ratio) to enable earlier risk stratification for preeclampsia (Event 1893) in pregnancies complicated by diabetes or GDM.
  2. DART Hazard Assessment & Chemical Grouping : As AhR activation is a shared MIE across multiple toxicological networks, this AOP provides a biological rationale for screening exogenous AhR agonists and modulators (e.g., environmental dioxin-like pollutants or pharmaceuticals) for placenta- and vascular-mediated developmental and reproductive toxicity (DART). It directly informs chemical profiling and Integrated Approaches to Testing and Assessment (IATA) using human first-trimester trophoblast (HTR-8/SVneo) and endothelial (HUVEC) assays.
  3. Targeted Therapeutic Interventions: Mapping this intermediate signaling cascade uncovers pharmacological targets beyond conventional low-dose aspirin prophylaxis. Specifically, attenuating aberrant AhR hyperactivation, restoring PPAR-gamma transactivation (Event 233), or modulating PGE2–EP receptor signaling represent promising preclinical targets for preventing placental dysfunctions in high-risk diabetic pregnancies.
  4. Regulatory Limitations: Due to current knowledge gaps regarding exact quantitative CML thresholds for AhR activation at the human maternal-fetal interface and bidirectional PGE2 signaling kinetics, this AOP should currently be applied for qualitative read-across and screening-level hazard identification rather than deriving quantitative points of departure (PODs) for regulatory exposure limits.

References

List of the literature that was cited for this AOP. More help

Bautista-Bautista G, Flores-Herrera H, et al. Escherichia coli induced matrix metalloproteinase-9 activity and type IV collagen degradation is regulated by progesterone in human maternal decidua. BMC Pregnancy Childbirth. 2024;24(1):645.

Jia JP, Wu JH, Hu JR. PGE2/EP4 signaling downregulates PPAR-gamma expression and impairs trophoblast differentiation in human placenta. Eur Rev Med Pharmacol Sci. 2022;26(3):771-778.

Jiang H, Meng H, Yang Y, et al. Infection-related preterm birth and maternal vascular pathology. Front Cardiovasc Med. 2025;12:1567127.

Jiang Y, Zhu Y, Shi Y, et al. Extracellular matrix stiffness regulates extravillous trophoblast invasion and migration. PLoS One. 2013;8(7):e69079.

Khankin EV, Royle C, Karumanchi SA. Placental hypoxia and antiangiogenic factors in preeclampsia. Semin Thromb Hemost. 2010;36(3):309-320.

Kobara H, Miyamoto T, Shiozawa T, et al. Peroxisome proliferator-activated receptor gamma (PPARgamma) regulates MMP-2 and MMP-9 expression in extravillous trophoblasts. Placenta. 2013;34(11):1036-1043.

Lee WJ, Liu SH, Sheu ML, et al. Aryl hydrocarbon receptor deficiency attenuates oxidative stress-related mesangial cell activation and macrophage infiltration and extracellular matrix accumulation in diabetic nephropathy. Antioxid Redox Signal. 2016;24(4):217-231.

Li Y, Wang K, Zheng J, et al. Altered COX-2/PGE2 signaling in human placenta and maternal vasculature during preeclampsia. Med Hypotheses. 2015;84(5):510-513.

Li Y, Zheng J, et al. Roles of aryl hydrocarbon receptor in endothelial angiogenic responses. Biol Reprod. 2020;103(5):927-937.

Preeclampsia Organoid Study Group. Constructing a preeclampsia organoid model to elucidate the mechanism of aspirin. Hypertension. 2025;82(4):800-803.

Rana S, Lemoine E, Granger JP, Karumanchi SA. Preeclampsia: pathophysiology, challenges, and perspectives. Circ Res. 2019;124(7):1094-1112.

Roberts JM, Myatt L, et al. Pathophysiology of preeclampsia: focus on endothelial dysfunction. Hypertension. 2021;77(5):1430-1441.

Smoking Mouse Model Study Group. The role of the aryl hydrocarbon receptor in vascular factors related to preeclampsia in a smoking mouse model. Curr Issues Mol Biol. 2024;46(1):749-760.

Tossetta G, Giannubilo SR, et al. Fibronectin and lumican expression in preeclamptic placentas and their role in trophoblast dysfunction. J Cell Physiol. 2019;234(5):6091-6098.

Vogel CF, Li W, Matsumura F, et al. Dual path of cyclooxygenase-2 expression in TCDD-treated human monocytic cells. Am J Pathol. 2007;171(5):1538-1548.

Zhao YJ, Zhou C, Zheng J, et al. Defective uterine spiral artery remodeling and placental insufficiency in preeclampsia. J Physiol. 2023;603(2):579-594.

Zhou C, Zheng J, et al. Vascular endothelial dysfunction and anti-angiogenic balance in preeclampsia. Hypertension. 2019;74(1):154-163.